Heart Failure
Conditions
Keywords
Heart Failure, Therapeutics, Blood volume
Brief summary
Heart failure is a common cardiac condition affecting nearly 6 million Americans. Silent blood volume overload is common in patients with heart failure and is associated with increased risk of death. This study is designed to determine if adjustment of therapy based on direct measurement of blood volume will reduce risk of hospitalization and death when compared with therapy based on clinical assessment of blood volume in patients with chronic heart failure.
Detailed description
Multicenter prospective randomized trial to compare heart failure management strategies based on clinical assessment of volume status vs. direct measurement of blood volume with a radioisotope technique. Subjects will be randomly assigned to a standard care strategy with guideline recommended treatment based on serial clinical assessment of blood volume or a measured blood volume strategy with guideline recommended treatment based on serial measured blood volume. All subjects will undergo blood volume measurement procedures, but the testing results will only be returned to the physician in the group assigned to management according to measured blood volume status. Subjects will be blinded to their study treatment assignment status.
Interventions
OTHERDaxor Blood Volume Analysis
Radiolabeled albumin for direct measurement of blood volume
OTHERClinical volume status assessment
Volume assessment based on history and physical examination
Sponsors
Daxor Corporation
NYU Langone Health
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age \>21 years * Discharge from hospital or emergency department observation unit with a primary diagnosis of acute decompensated heart failure * Planned discharge home * Able and willing to provide informed consent
Exclusion criteria
* Significant co-morbidity during heart failure hospitalization (treated pneumonia, sepsis, respiratory failure, oliguric renal failure, major bleeding requiring transfusion, stroke) * Heart failure primarily due to significant valvular disease, sub-aortic outflow obstruction, active myocardial ischemia, apical ballooning syndrome, active arrhythmias, active myocarditis, primary restrictive cardiomyopathy, pericardial disease, or congenital heart disease * Other major co-morbidities that increase mortality risk (stroke with hemiplegia, diabetes with end-organ damage other than heart disease, history of cancer in last 2 years, moderate to severe liver disease, HIV infection with AIDS) * Hospitalization length of stay \>10 days * Evidence of acute coronary syndrome during qualifying heart failure hospitalization * Planned revascularization procedure within 6 months * Planned implantation of ICD or pacemaker within 6 months * Planned placement on cardiac transplantation list within 6 months * Planned other major cardiac surgery or other surgery within 6 months * Planned intermittent or continuous intravenous positive inotropic therapy * Planned intermittent or continuous intravenous vasodilator therapy * Severe obesity (BMI ≥ 40 kg/m2) or cachexia (BMI ≤18 kg/m2) * Severe chronic kidney disease (estimated GFR\<30 ml/min (Modification of Diet in Renal Disease formula20)) * Hemoglobin \< 10 gm/dl * Non-cardiac primary limitation to exercise (rheumatological, orthopedic, pulmonary, neurological or peripheral vascular disease) * Known history of non-adherence with medications * Psycho-social factors that interfere with ability to adhere to study procedures (dementia, active substance abuse, poorly controlled psychiatric illnesses, inability to travel frequently to the study center) * Pregnant women or nursing mothers * Women of childbearing potential not using adequate birth control methods * Known hypersensitivity to iodine, eggs, or any other component of the Volumex injection kit * History of anaphylaxis * Participation in another heart failure investigational treatment protocol currently or \<30 days
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hospitalization-free Survival | 6 months |
Secondary
| Measure | Time frame |
|---|---|
| Cardiovascular mortality | 6 months |
| Heart failure hospitalization | 6 months |
| Quality of life questionnaire (KCCQ) | 6 months |
| 6 minute walk test | 6 months |
| Hospitalization for worsening renal function | 6 months |
| All cause hospitalization | 6 months |
| All cause mortality | 6 months |
Countries
United States
Outcome results
None listed